- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01403350
Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan
Effectiveness of Community Level Deployment of Rapid Diagnostic Tests for Malaria in Afghanistan: Cluster Randomised Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a cluster randomised trial conducted in 22 clinics (clusters) in two provinces of Afghanistan. Clinics in Afghanistan have a number of community health workers (CHWs) who are residents of villages near to the clinic. The clinic provides them with their supplies of drugs and other items (e.g. family planning interventions) and the CHW provides a range of services in the community including treatment of acute episodes of fever. Currently, the CHW has no way of diagnosing malaria, except based on the presenting signs and symptoms of the patient. With this method is it likely that many patients who do not have malaria, but have a fever, are treated with antimalarial drugs and some patients with malaria are likely not to be treated with an antimalarial drug.
The use of Rapid Diagnostic Tests (RDT) for malaria could potentially provide the CHW with an easy and safe way of diagnosing malaria based on the presence or absence of parasites in the blood. However, use of tests is not straightforward. They need to be applied correctly, following a strict protocol, to be accurate. There is now much interest in widespread deployment of these tools which are recommended by the World Health Organisation for all fever patients in malaria endemic areas. However, evidence for their effectiveness when used by CHWs is patchy and there are no randomised trials that have been conducted in Asia. Since they represent a considerable cost, examination of their effectiveness is required.
In Asia (unlike most of Africa), malaria is caused by two species - Plasmodium vivax accounts for the majority of cases and P. falciparum for the minority. Treatments differ between the species because of differing drug resistance patterns. Therefore accurate diagnosis is important for providing accurate treatment for the different types of malaria and also for treatment of cases of fever who do not have malaria with alternative treatments. In areas where health services are restricted by short opening hours, insecurity, or inaccessibility due to distance or terrain, the CHW should be able to use RDTs and apply the correct treatment for both a positive and a negative test at the village level.
This study will randomise 22 clinics (and their constituent CHWs) to receive either an RDT for use by the CHW in diagnosing malaria in patients with fever, or no intervention (the current situation) where CHWs base their treatment decisions on symptoms alone (i.e. there is no parasite based diagnosis). The RDT group will be given the standard national training for use of RDTs and management of malaria and the standard supplies. The non-RDT arm will have training on management of malaria and a short introduction to RDTs. The study will measure the accuracy of treatment applied by the CHW in the RDT vs. the non-RDT arms, and examine the accuracy of the RDT itself when it is applied in the field under operational conditions. The accuracy will be measured by collecting filter paper blood spots from the patients which will be tested by PCR for malaria. A variety of comparisons will be made between the two groups, but the main aim is to measure and difference in accurate treatment of the patients according to the reference (PCR) diagnosis.
In phase II of the study the non-RDT arm will be discontinued and the clinics will be re-randomised to different interventions. One group of clinics will have the standard RDT roll out continued, as previously, and the second group will get additional training and a range of supportive interventions to assist in their practice. The second phase will use the same methods of assessing the study outcomes. The aim of the second phase is to see whether additional training (and cost) results in improved practice by CHWs.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kabul, Afghanistan, 0000
- Health Protection and Research Organisation
-
Kunduz, Afghanistan
- Merlin
-
-
Nangahar
-
Jalalabad, Nangahar, Afghanistan
- HealthNet TPO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Any patient where the CHW* or clinician considers malaria in the diagnosis - either prescribing an antimalarial or would request a malaria test if available or referring for diagnosis of malaria elsewhere.
* *any community health worker who consults with patients and prescribes treatment, and is administratively attached to one of the study clinics.
- Patient, or parent/guardian, gives informed consent to the study.
Exclusion Criteria:
- Patients with a diagnostic result from another facility.
- Patients referred on for diagnosis in the private sector.
- Patients who have signs of severe or complicated disease and are referred prior to giving any diagnosis using the interventions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Current Practice
Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
|
|
ACTIVE_COMPARATOR: Intervention Arm
Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
|
Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of cases correctly treated
Time Frame: Outcomes measured during consultation - approximately 30-40 minutes
|
Correctly treated defined as: Those with PCR positive blood sample given an appropriate antimalarial; Those with PCR negative blood sample not given any antimalarial |
Outcomes measured during consultation - approximately 30-40 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of falciparum patients treated with artesunate combination therapy
Time Frame: Outcomes measured during consultation - approximately 30-40 minutes
|
Measured against the PCR result from the blood sample
|
Outcomes measured during consultation - approximately 30-40 minutes
|
Accuracy of the RDT
Time Frame: Outcomes measured during consultation - approximately 30-40 minutes
|
Sensitivity and specificity measured against the PCR blood sample
|
Outcomes measured during consultation - approximately 30-40 minutes
|
Accuracy of treatment given by the CHW in response to the RDT result
Time Frame: Outcomes measured during consultation - approximately 30-40 minutes
|
Proportion of patients with a positive RDT not given and appropriate antimalarial Proportion of patient with a negative RDT who are given any antimalarial
|
Outcomes measured during consultation - approximately 30-40 minutes
|
Cost effectiveness of the intervention(s)
Time Frame: Outcomes measured during consultation - approximately 30-40 minutes
|
Comparative cost-effectiveness between the arms
|
Outcomes measured during consultation - approximately 30-40 minutes
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5911
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Department of Health and Human ServicesNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on Malaria Rapid Diagnostic test
-
London School of Hygiene and Tropical MedicineKilimanjaro Christian Medical Centre, TanzaniaCompletedMalaria | Febrile IllnessTanzania
-
Centro de Investigação em Saúde de ManhiçaUniversity of California, San Francisco; Barcelona Institute for Global Health and other collaboratorsRecruitingMalaria | Malaria in Pregnancy | Malaria,FalciparumMozambique
-
Institute of Tropical Medicine, BelgiumWithdrawn
-
DBL -Institute for Health Research and DevelopmentLondon School of Hygiene and Tropical Medicine; Ministry of Health, Uganda; Artemisinin-based...Completed
-
Centro per le Malattie TropicaliInstitute of Tropical Medicine, BelgiumCompleted
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Moi UniversityCompleted
-
London School of Hygiene and Tropical MedicineGhana Health ServicesCompleted
-
Abbott Rapid DxBill and Melinda Gates FoundationCompleted
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
Ghana Health ServicesLondon School of Hygiene and Tropical MedicineCompleted